Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT05223751
Other study ID # 2021-XXXX-LGHP
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date February 7, 2022
Est. completion date February 15, 2025

Study information

Verified date February 2024
Source Lancaster General Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a prospective, randomized, controlled clinical trial in which participants with NYHA class II or III and symptomatic Heart Failure with reduced Ejection Fraction (HFrEF) (Ejection Fraction (EF) ≤ 45%) will be assigned to one of two treatment groups: standard of care or breathing therapy.


Description:

To evaluate the effect of breathing training on the 6-minute walk test in a population of heart failure patients. Enrollment/Baseline Visit During the enrollment visit, the participant will meet with the clinical research coordinator (CRC) to review any final questions regarding the study and the informed consent form will be signed. The enrollment visit must occur within one month of screening. Once the informed consent is signed, the following procedures will occur. - Randomization: Participants will be randomized using REDCap in a 2:1 blocking method into the intervention group (breathing therapy) or the control (standard of care). - N-terminal (NT)-pro hormone BNP (NT-proBNP): If an NT-proBNP was collected as standard of care within 3 months of enrollment, this can be used for study purposes and compared to the 6 month NT-proBNP. - New York Heart Association Class: If the NYHA class is completed as standard of care within 3 months of enrollment, this can be used for study proposes. - Kansas City Cardiomyopathy Questionnaire (KCCQ) - Respiratory Rate - Peak Expiratory Flow - 6-minute walk test - Orientation to the Heart Rate Variability 4 (HRV4) Training application: This will include downloading, creating an account for, and training the participant on the application. The Intervention Group will also receiving training on the Meo Health breathing therapy, which will include: - Being shown the Meo Health Breathing Therapy On-Boarding video - Orientation to breathing application: Participants will be assisted in downloading and custom setting the Breathe application. - Zoom Within one month of the baseline visit, participants in the intervention group will have a one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their breathing therapy intervention. 3 Month Visit The 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group . The participant will only meet with the CRC at the 3 month visit and all assessments will be completed by the CRC. - NYHA class - KCCQ - Respiratory Rate - Peak Expiratory Flow - 6-minute walk test - Assess compliance from HRV4 Training application questions - Assess any possible adverse events 6 Month/Final Visit The 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group. The participant will meet with the CRC at the 6 month visit, any assessments not completed as Standard of Care (SOC), will be completed by the CRC. - NT-proBNP: If an NT-proBNP is ordered as standard of care for the participant, this can be used for study purposes and compared to the baseline NT-proBNP. - NYHA class: If the NYHA class is completed as standard of care, this can be used for study purposes and compared to the baseline and 3 month values. - KCCQ - Respiratory Rate - Peak Expiratory Flow - 6-minute walk test - Assess any possible adverse events 9 Month Structured Telephone Survey The 9 month structured telephone interview will take place for all participants who receive breathing training from Meo Health. Participants will be called by a study team member who will facilitate a short (3-5 minute) telephone survey about adherence and changes in health outcomes as a result of participation in the trial. (See appendix 15.4). The study team member will record all answers into REDCap. Upon completion of the survey, participants will be closed out of the study. If a study team member is unable to get in contact with a participant after two attempts, their status will be marked as "closed to follow-up" and they won't be interviewed.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 114
Est. completion date February 15, 2025
Est. primary completion date February 15, 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. 18 years or older 2. Signed informed consent 3. NYHA class II-III heart failure 4. EF = 45% (echo within 1 year of enrollment) 5. At least 30 days of stable medical regimen (no new neurohormonal blockade or Sodium-glucose co-transporter 2 inhibitors (SGLT2i). Dose adjustments allowed) 6. Likely to be compliant with breath training as assessed by the provider 7. Availability of a "smart" phone and internet access 8. Established care at Lancaster General Health Penn Medicine Exclusion Criteria: 1. Cardiac resynchronization therapy (CRT) within 6 months 2. Severe Chronic obstructive pulmonary disease (COPD) 3. History of diaphragm paralysis 4. Unable or unwilling to complete respiratory training protocol 5. Decompensated or American College of Cardiology (ACC) Stage D Heart Failure (HF) 6. Prior or planned chest/abdominal or nasal/facial surgery within 6 months 7. Neuromuscular disease which impairs respiration 8. Diagnosed cognitive impairment (unable to participate in training) 9. Untreated obstructive severe sleep apnea (AHI > 30) 10. Severe valvular heart disease 11. Uncontrolled atrial fibrillation (Ave Heart Rate (HR) > 100 bpm) 12. Orthopedic or other limitations which impair the 6-minute walk test

Study Design


Intervention

Behavioral:
Meo Health Breathing and humming exercises
The Intervention Group will receive training on the Meo Health breathing therapy, which will include: Being shown the Meo Health Breathing Therapy On-Boarding video Orientation to breathing application: Participants will be assisted in downloading and customizing the Breathe application. Zoom tutorial: Participants will be assisted in setting up and navigating Zoom application for use with the Meo Health breathing coach. Within one month of the baseline visit, participants in the intervention group will have a 20 minute one-on-one training session with the Meo Health breathing coach. This will mark the beginning of their respiratory training intervention. A 3 month visit will occur 3 months (± 14 days) from the one-on-one training session for participants in the intervention group. A 6 month visit will occur 6 months (± 14 days) from the one-on-one training session for participants in the intervention group.

Locations

Country Name City State
United States Lancaster General Hospital Lancaster Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Lancaster General Hospital Louise von Hess Medical Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline to 6 months for the 6-minute walk test (6MWT) Distance (m) covered in six minutes from baseline to 6 months Baseline, 6 months
Secondary Kansas City Cardiomyopathy Questionnaire 12 (KCCQ12) quality of life score Change in Kansas City Cardiomyopathy Questionnaire 12 - Quality of Life (KCCQ12-QL) score
KCCQ12-QL score corresponds to Questions 6 and 7. Responses are coded as follows:
Question 6 Response It has extremely limited my enjoyment of life = 1 It has limited my enjoyment of life quite a bit = 2 It has moderately limited my enjoyment of life = 3 It has slightly limited my enjoyment of life = 4 It has not limited my enjoyment of life at all = 5
Question 7 Response Not at all satisfied = 1 Mostly dissatisfied = 2 Somewhat satisfied = 3 Mostly satisfied = 4 Completely satisfied = 5
If responses to both questions are missing, no score is computed. Otherwise, the score is calculated by taking the average of the non-missing responses and rescaling to 0-100, as follows:
KCCQ12-QL = 100*[(average of Questions 6 and 7) - 1]/4
Scores are scaled 0-100, where 0 denotes the lowest reportable health status and 100 the highest.
Baseline, 3 months, 6 months
Secondary Pulmonary parameters: Peak expiratory flow Change in peak expiratory flow spirometry Baseline, 3 months, 6 months
Secondary New York Heart Association (NYHA) Class (graded I-IV) Proportion Improved 1 Class Proportion of subjects that decreased 1 NYHA class.
NYHA Classification - The Stages of Heart Failure:
Class I - Cardiac disease, but no symptoms and no limitation in ordinary physical activity.
Class II - Mild symptoms and slight limitation during ordinary activity. Class III - Significant limitation in activity due to symptoms. Comfortable only at rest.
Class IV - Severe limitations. Symptoms even while at rest. No NYHA class listed or unable to determine.
Baseline, 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT02499601 - CORolla® TAA for Heart Failure With Preserved Ejection Fraction (HFpEF) and Diastolic Dysfunction (DD) N/A
Completed NCT02537041 - Non-invasive Evaluation of Myocardial Stiffness by Elastography N/A
Completed NCT02275793 - The Regulation of Pulmonary Vascular Resistance in Patients With Heart Failure
Withdrawn NCT00773084 - Aliskiren and Renin Inhibition in Diastolic Heart Failure N/A
Terminated NCT00293150 - Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure Phase 4
Terminated NCT01942395 - Dietary Approaches to Stop Hypertension in 'Diastolic' Heart Failure 2 (DASH-DHF 2) N/A
Recruiting NCT03157219 - Manipal Heart Failure Registry (MHFR) N/A
Terminated NCT01778894 - Mathematical Modeling to Determine Basic Muscle Properties in the Failing Heart
Completed NCT04154878 - 2 New Measurements Used to Describe the Filling Phase of the Left Ventricle (LV).
Recruiting NCT01599117 - A Randomized Trial of Udenafil Therapy in Patients With Heart Failure With Preserved Ejection Fraction [ULTIMATE-HFpEF] Phase 3
Completed NCT01185067 - Physiological Effects of Grape Seed Extract in Diastolic Heart Failure Phase 1
Completed NCT03338374 - Cardiac Resynchronisation Therapy Versus Rate-responsive Pacing in Heart Failure With Preserved Ejection Fraction N/A
Completed NCT02589977 - Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF Phase 4
Completed NCT02147613 - High Intensity Interval Exercise in Diastolic Heart Failure N/A
Terminated NCT00083772 - Use of Nesiritide in the Management of Acute Diastolic Heart Failure Phase 4
Completed NCT00303498 - A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure Phase 2
Terminated NCT02254382 - Positive Airway Pressure Therapy Study in Sleep Apnea and Diastolic Heart Failure N/A
Completed NCT00839228 - Perhexiline Therapy in Heart Failure With Preserved Ejection Fraction Syndrome Phase 2
Terminated NCT00662116 - Beginning a Randomized Evaluation of the AGE Breaker Alagebrium in Diastolic Heart Failure (BREAK-DHF-I) Phase 2
Completed NCT02084992 - A Study of a Technology-enabled Disease Management Program to Reduce Hospitalizations for Heart Failure N/A